Head to Head Comparison: InspireMD (NSPR) versus Its Competitors

InspireMD (NYSE:NSPR) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its competitors? We will compare InspireMD to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, risk, earnings, profitability and dividends.

Profitability

This table compares InspireMD and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
InspireMD Competitors	-278.24%	-150.08%	-21.87%

Risk & Volatility

InspireMD has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, InspireMD’s competitors have a beta of 2.56, indicating that their average stock price is 156% more volatile than the S&P 500.

Insider and Institutional Ownership

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 25.0% of InspireMD shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares InspireMD and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
InspireMD	$10.84 million	-$19.92 million	-1.20
InspireMD Competitors	$1.88 billion	$139.14 million	11.28

InspireMD’s competitors have higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for InspireMD and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0	0	3	0	3.00
InspireMD Competitors	4264	10500	18236	825	2.46

InspireMD presently has a consensus price target of $4.50, suggesting a potential upside of 485.18%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 17.10%. Given InspireMD’s stronger consensus rating and higher possible upside, equities research analysts clearly believe InspireMD is more favorable than its competitors.

Summary

InspireMD competitors beat InspireMD on 7 of the 13 factors compared.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.